141 related articles for article (PubMed ID: 33337849)
1. Serum miR-3180-3p and miR-124-3p may Function as Noninvasive Biomarkers of Cisplatin Resistance in Gastric Cancer.
Jin L; Zhang Z
Clin Lab; 2020 Dec; 66(12):. PubMed ID: 33337849
[TBL] [Abstract][Full Text] [Related]
2. Serum microRNAs as potential new biomarkers for cisplatin resistance in gastric cancer patients.
Jin L; Zhang N; Zhang Q; Ding G; Yang Z; Zhang Z
PeerJ; 2020; 8():e8943. PubMed ID: 32328349
[TBL] [Abstract][Full Text] [Related]
3. Targeting Oncogenic miR-181a-2-3p Inhibits Growth and Suppresses Cisplatin Resistance of Gastric Cancer.
Jin L; Ma X; Zhang N; Zhang Q; Chen X; Zhang Z; Ding G; Yu H
Cancer Manag Res; 2021; 13():8599-8609. PubMed ID: 34815714
[TBL] [Abstract][Full Text] [Related]
4. Exosomal MiR-500a-3p promotes cisplatin resistance and stemness via negatively regulating FBXW7 in gastric cancer.
Lin H; Zhang L; Zhang C; Liu P
J Cell Mol Med; 2020 Aug; 24(16):8930-8941. PubMed ID: 32588541
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-95-3p serves as a contributor to cisplatin resistance in human gastric cancer cells by targeting EMP1/PI3K/AKT signaling.
Ni Q; Zhang Y; Tao R; Li X; Zhu J
Aging (Albany NY); 2021 Mar; 13(6):8665-8687. PubMed ID: 33714198
[TBL] [Abstract][Full Text] [Related]
6. MiR-876-3p regulates cisplatin resistance and stem cell-like properties of gastric cancer cells by targeting TMED3.
Peng C; Huang K; Liu G; Li Y; Yu C
J Gastroenterol Hepatol; 2019 Oct; 34(10):1711-1719. PubMed ID: 30843262
[TBL] [Abstract][Full Text] [Related]
7. Identification of non-invasive biomarkers for chronic atrophic gastritis from serum exosomal microRNAs.
Liu H; Li PW; Yang WQ; Mi H; Pan JL; Huang YC; Hou ZK; Hou QK; Luo Q; Liu FB
BMC Cancer; 2019 Feb; 19(1):129. PubMed ID: 30736753
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-574-3p regulates epithelial mesenchymal transition and cisplatin resistance via targeting ZEB1 in human gastric carcinoma cells.
Wang M; Zhang R; Zhang S; Xu R; Yang Q
Gene; 2019 Jun; 700():110-119. PubMed ID: 30917930
[TBL] [Abstract][Full Text] [Related]
9. Low SP1 SUMOylation-dependent SNHG17 upregulation promotes drug resistance of gastric cancer through impairing hsa-miR-23b-3p-induced Notch2 inhibition.
Huang G; Cai G; Hu D; Li J; Xu Q; Chen Z; Xu B
Cell Oncol (Dordr); 2022 Dec; 45(6):1329-1346. PubMed ID: 36214997
[TBL] [Abstract][Full Text] [Related]
10. MiR-223 promotes the cisplatin resistance of human gastric cancer cells via regulating cell cycle by targeting FBXW7.
Zhou X; Jin W; Jia H; Yan J; Zhang G
J Exp Clin Cancer Res; 2015 Mar; 34(1):28. PubMed ID: 25888377
[TBL] [Abstract][Full Text] [Related]
11. miR-149 reverses cisplatin resistance of gastric cancer SGC7901/DDP cells by targeting FoxM1.
Li X; Liang J; Liu YX; Wang Y; Yang XH; Luan BH; Zhang GL; Du J; Wu XH
Pharmazie; 2016 Nov; 71(11):640-643. PubMed ID: 29441968
[TBL] [Abstract][Full Text] [Related]
12. Plasma microRNAs as potential new biomarkers for early detection of early gastric cancer.
Zhu XL; Ren LF; Wang HP; Bai ZT; Zhang L; Meng WB; Zhu KX; Ding FH; Miao L; Yan J; Wang YP; Liu YQ; Zhou WC; Li X
World J Gastroenterol; 2019 Apr; 25(13):1580-1591. PubMed ID: 30983818
[TBL] [Abstract][Full Text] [Related]
13. miR-21 modulates cisplatin resistance of gastric cancer cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway.
Gu Y; Fei Z; Zhu R
Anticancer Drugs; 2020 Apr; 31(4):385-393. PubMed ID: 31913198
[TBL] [Abstract][Full Text] [Related]
14. PCAT-1 contributes to cisplatin resistance in gastric cancer through miR-128/ZEB1 axis.
Guo Y; Yue P; Wang Y; Chen G; Li Y
Biomed Pharmacother; 2019 Oct; 118():109255. PubMed ID: 31352238
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
16. Identification of upregulated exosomal miRNAs between A2780 and A2780/DDP human ovarian cancer cells by high-throughput sequencing.
Wang H; Liu L; Liu Q; Zheng J; Zheng Q; Chen Y; Xia H; Wu Q; Sun Y
J Ovarian Res; 2023 May; 16(1):94. PubMed ID: 37179363
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-362-5p enhances the cisplatin sensitivity of gastric cancer cells by targeting suppressor of zeste 12 protein.
Wei X; Gao M; Ahmed Y; Gao M; Liu W; Zhang Y; Xie X; Zhao Q; Wang H; Gu K
Oncol Lett; 2019 Aug; 18(2):1607-1616. PubMed ID: 31423228
[TBL] [Abstract][Full Text] [Related]
18. MiR-199a-3p enhances breast cancer cell sensitivity to cisplatin by downregulating TFAM (TFAM).
Fan X; Zhou S; Zheng M; Deng X; Yi Y; Huang T
Biomed Pharmacother; 2017 Apr; 88():507-514. PubMed ID: 28126676
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin-resistant MDA-MB-231 Cell-derived Exosomes Increase the Resistance of Recipient Cells in an Exosomal miR-423-5p-dependent Manner.
Wang B; Zhang Y; Ye M; Wu J; Ma L; Chen H
Curr Drug Metab; 2019; 20(10):804-814. PubMed ID: 31424364
[TBL] [Abstract][Full Text] [Related]
20. Upregulated microRNA-193a-3p is responsible for cisplatin resistance in CD44(+) gastric cancer cells.
Lee SD; Yu D; Lee DY; Shin HS; Jo JH; Lee YC
Cancer Sci; 2019 Feb; 110(2):662-673. PubMed ID: 30485589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
